Integrating biodiversity into pharma sustainability strategy

Biodiversity is becoming an increasingly important part of corporate sustainability strategy as regulators, investors, and other stakeholders call for greater transparency around how companies affect and depend on nature. Emerging frameworks such as the Taskforce on Nature-related Financial Disclosures (TNFD) are helping organisations evaluate these relationships more systematically by considering nature-related impacts, dependencies, risks, and opportunities across their operations and value chains.
A structured, science-based nature assessment approach
In support of a leading animal health company, Ramboll developed a structured, TNFD LEAP-aligned approach to help the company assess its nature-related impacts, dependencies, risks, and opportunities across global operations. We worked with the client to help move beyond a general understanding of biodiversity and toward a more practical framework for identifying where operations may have the greatest interactions with nature, including biodiversity, water resources, ecosystem services, and the broader environmental conditions that support animal and human health.
Our experts designed the approach to support both internal decision-making and external reporting readiness. By aligning the assessment with TNFD guidance and emerging European reporting expectations, including the Corporate Sustainability Reporting Directive (CSRD), Ramboll helped the company establish a clearer process for evaluating nature-related considerations as part of broader sustainability and risk management efforts. This included identifying priority areas where additional data collection, analysis, or site-level review may be warranted.
Overall, our work provided a foundation for future disclosure, target setting, and nature-related action. It also helped translate complex biodiversity and nature-risk concepts into a more actionable roadmap that the company can use to inform strategy, strengthen internal alignment, and advance a more consistent approach to managing nature-related issues across its global footprint.
Translating strategy into a roadmap
Once the strategy was developed, Ramboll prepared a roadmap aligned with the TNFD LEAP approach, recognising that TNFD is designed to be an iterative process that improves as additional information, site-level context, and organisational priorities are better understood. The roadmap built on lessons learned during the initial screening and outlined how the client could continue refining its assessment of biodiversity-related risks and opportunities, prioritise future analyses, and advance toward more robust nature-related disclosure and performance management.
In a subsequent phase, our experts applied those lessons through a TNFD-aligned biodiversity assessment of manufacturing sites and contract manufacturing organisations.
Ramboll is also supporting related value chain work to help the client better understand nature-related dependencies, impacts, risks, and opportunities beyond its direct operations. Using biodiversity screening methodologies and in-house Ramboll tools, we evaluated biodiversity-sensitive geographies, assessed nature-related dependencies and impacts, and identified opportunities to strengthen data collection, improve future assessments, and support practical nature-related action.
Turning insight into action
Together, the strategy, assessments, and roadmap gave the client a clearer view of where to prioritise future action while supporting alignment with emerging nature-related disclosure expectations. The client now has a practical foundation for integrating biodiversity considerations into decision-making across its operations and is better positioned to advance a more resilient sustainability programme.
RELATED PROJECTS
Explore more within Life Sciences and Pharma
Discover how Ramboll helps pharma and biopharma organisations develop advanced manufacturing sites that enhance market readiness and shorten time‑to‑market for new therapies.
